As the equities market recovered at the turn of the year, so did Crispr Therapeutics $CRSP. After falling to about $22 in late December, it has rebounded to about $37.15 a month later. But here it faces resistance up to the $40 handle. In such a tentative market, I believe the market will be a net seller of CSRP at these prices.CRSP Daily Chart(click to enlarge)Falling Resistance and RSI:- If the market is still in bearish correction mode, it should respect the falling trendline (seen on the daily chart above) as resistance.- This trendline is reinforced by the 100-day simple moving average (SMA). - More importantly the RSI is right around 60. If the market still has bearish momentum, it turn the RSI down below 60, forgiving a couple sessions above it. $40 Resistance:- There is also a strong possibility that price will push through this falling resistance because the general market has shifted from bearish to a more sideways consolidation. - In this scenario, we can expect a push to $40. But here we see a support/resistance pivot, that was common resistance since September 2018. - If the RSI is around 70 and price is around $40, I would also expect sellers.Downside:- The downside is limited to how bearish the overall market is right now. - The recent recovery can dissipate at any time. If the markets go back into bearish mode, CRSP is likely going to revisit the December low around $22, with a possible reach towards $20. - But if the general market has indeed shifted into sideways mode, CRSP has more of a chance to consolidate sideways as well. - In this scenario, we might see price find support as high as $30. If not, we should still limit the downside to $25 during a non-bearish market environment. My Strategy:- Because there is no way to predict the mode of the market in 2019, I will prepare some dry powder for CRSP at $20 in case the worst is not over. - At the same time, I want to start averaging in around $30. - What I don't want to do right now is to chase the current rebound thinking this is the market bottom. IT CAN be, and within this context I think price can still revisit $30 and I would still have a chance to be exposed to a possible market recovery. - But I would not go heavy on this bullish outlook.